Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received a clinical trial notice from the Center for Drug Evaluation of China’s National Medical Products Administration for SKB565, an investigational dual-payload antibody-drug conjugate intended for patients with advanced solid tumors. The decision allows the Hong Kong-listed biotechnology company, which trades under stock code 6990, to move its first dual-payload ADC into clinical development, but it does not constitute marketing approval or evidence that the therapy is effective in patients.
SKB565 was developed using Kelun-Biotech’s OptiDC drug-conjugate platform. The company describes the molecule as carrying both a tumor-killing toxin and an immunomodulatory payload, an architecture intended to combine direct cancer-cell destruction with activation of antitumor immunity inside the tumor microenvironment. Kelun-Biotech reported encouraging preclinical activity and safety findings, although those claims have not yet been supported by human data disclosed publicly.
A public trial record identifies a planned Phase 1/2 study involving an estimated 180 adults with advanced solid tumors. The programme is expected to include dose escalation, dose expansion and indication-specific expansion stages, with early evaluation focused on tolerability, dose-limiting toxicities, pharmacokinetics and preliminary antitumor activity. The registry continued to describe the study as not yet recruiting in the latest accessible record.
The significance of the regulatory notice therefore lies less in what SKB565 has already demonstrated and more in what Kelun-Biotech is now permitted to investigate. The molecule represents a deliberate attempt to compress an ADC and an immunotherapy strategy into one drug, but the clinical programme must still establish whether that added biological ambition produces a manageable medicine rather than simply a more complicated one.
Why does the SKB565 clinical trial notice matter for Kelun-Biotech’s ADC plus immunotherapy strategy?
Kelun-Biotech has already been exploring the combination of antibody-drug conjugates with immune-oncology treatments through multi-drug regimens. These include clinical programmes combining its ADC assets with PD-1 or PD-L1 inhibitors and studies involving SKB118, the company’s PD-1 and VEGF bispecific antibody.
SKB565 takes that strategy in a different direction. Instead of administering an ADC and a separate immune-modulating medicine, the company is attempting to attach two functionally different payloads to the same antibody-based delivery system. One component is intended to kill targeted tumor cells, while the second is designed to influence immune activity within the tumor microenvironment.
In theory, this could align the location and timing of the two mechanisms more closely than a conventional combination regimen. Tumor-cell injury caused by the toxin could release antigens or inflammatory signals while the immunomodulatory payload acts in the same local environment. Such coordination could potentially support a broader or more durable antitumor response.
That logic remains a hypothesis rather than an established clinical advantage. The quantity of each payload reaching a tumor, the sequence in which they are released and the duration of exposure may all affect whether the two mechanisms reinforce or interfere with one another. The immunomodulatory component must also remain sufficiently localized to avoid provoking unacceptable systemic inflammation.
The identities of the antigen, toxin and immunomodulator were not stated in Kelun-Biotech’s July 27 announcement. The company also did not disclose the drug-to-antibody ratio, linker configuration, release characteristics or the individual tumor types expected to enter the first expansion cohorts. Those omissions do not invalidate the programme, but they limit the conclusions that can currently be drawn about differentiation, competitive positioning and the likely safety profile.
What must the Phase 1/2 SKB565 trial establish before efficacy can be meaningfully judged?
The planned Phase 1/2 study is designed to enrol adults aged 18 to 75 with histologically or cytologically confirmed advanced solid tumors. Eligible patients are expected to have exhausted standard treatment, have no suitable standard option available or be unable to tolerate established therapy.
The dose-escalation stage will be the first meaningful test of Kelun-Biotech’s design. Investigators will need to determine how exposure changes across dose levels, whether both payloads behave predictably and which adverse events become dose limiting. The trial’s early priorities are therefore safety, tolerability and dose selection, not definitive proof of clinical benefit.
Pharmacokinetic analysis will be particularly important. Researchers may need to measure intact ADC, total antibody, released toxin, released immunomodulator and potentially additional metabolites or conjugated forms. Understanding how these components circulate, separate and clear from the body will be essential for interpreting both toxicity and biological activity.
The trial will also need to establish a recommended dose or dose range for expansion. A dose that maximizes delivery of the cytotoxic component may not produce the optimal immune effect, while a dose that strongly activates immune pathways could create inflammatory or off-target toxicities before maximum tumor-cell killing is reached.
Preliminary response rates may attract attention during dose escalation, especially in heavily treated patients. However, isolated responses across a mixed solid-tumor population would not establish that the dual-payload design is superior to a conventional ADC. Durability, target expression, prior therapies, tumor biology and the number of evaluable patients will determine how interpretable any early efficacy signal becomes.
Why do dual-payload ADCs create more difficult pharmacology and manufacturing challenges?
Dual-payload ADCs are emerging as a next-generation approach to address tumor heterogeneity, resistance and the limitations of carrying a single therapeutic agent. Designs under investigation include ADCs with two cytotoxic payloads and molecules, such as SKB565, that combine a toxin with an immune-modulating agent.
The attraction is straightforward. Cancer cells may not be equally sensitive to one cytotoxic mechanism, and tumors can evolve resistance under treatment pressure. Delivering two agents with complementary functions could make it more difficult for malignant cells to escape through a single resistance pathway.
The construction is considerably less straightforward. Developers must attach two payloads while preserving antibody binding, molecular stability, acceptable solubility and consistent drug distribution. Increasing payload density or introducing chemically different compounds can raise hydrophobicity, aggregation risk and variability between manufactured batches. Multivalent or branched linker systems may help, but they also create questions around payload release and analytical control.
Clinical pharmacology becomes more complicated because each payload may have different potency, distribution and elimination characteristics. Developers must understand not only the pharmacokinetics of the intact conjugate, but also the exposure and biological contribution of its individual components.
A 2026 clinical pharmacology review noted that no dual-payload ADC had yet secured regulatory approval and highlighted the increased number of analytes, possible immunogenicity and need to characterize interactions between the two mechanisms. This places SKB565 in an early and technically demanding part of the ADC field, where platform credibility will depend as much on reproducible manufacturing and interpretable pharmacology as on preclinical potency.
Can a toxin and immunomodulator overcome ADC resistance without creating excessive toxicity?
Kelun-Biotech has positioned SKB565 as a potential response to two common development challenges: incomplete tumor killing and the emergence of resistance. The cytotoxic payload is intended to provide immediate antitumor activity, while the immunomodulator is intended to activate immune responses that could continue attacking malignant cells.
That proposition will require several layers of clinical evidence. Investigators will need to show that the immunomodulatory payload remains biologically active after conjugation, reaches the intended tissue and produces measurable immune effects at doses patients can tolerate.
Biomarker analysis could become central to the programme. Useful measurements may include antigen expression, immune-cell infiltration, cytokine changes and markers of pathway activation before and after treatment. Without such evidence, it could be difficult to determine whether responses are being driven by the toxin alone or whether the second payload is making a meaningful contribution.
The safety analysis must look beyond adverse events typically associated with cytotoxic ADCs. Depending on the immunomodulatory mechanism, potential concerns could include inflammatory reactions, cytokine-related effects, liver abnormalities or immune-mediated toxicities. The actual risk profile cannot be inferred until the company discloses the payload and clinical data become available.
It would therefore be premature to describe SKB565 as safer, more durable or more effective than single-payload ADCs. The company’s preclinical findings support clinical investigation, but animal models cannot reproduce the full complexity of human immune responses, tumor heterogeneity or long-term toxicity.
How does SKB565 strengthen Kelun-Biotech’s wider antibody-drug conjugate franchise?
SKB565 enters development from a company that has progressed beyond the profile of a single-asset clinical-stage biotechnology group. Kelun-Biotech says it has more than 30 key innovative drug programmes, with four projects covering eight indications approved for marketing and more than 10 projects in clinical development. Its portfolio includes two marketed ADC programmes covering five indications.
The most commercially and strategically important component of its ADC franchise remains sacituzumab tirumotecan, also known as sac-TMT, SKB264 or MK-2870. Kelun-Biotech has been developing the TROP2-directed ADC in China while Merck & Co., Inc. controls development and commercial rights in much of the rest of the world.
Recent Phase 3 activity involving sac-TMT and pembrolizumab in non-small cell lung cancer has strengthened investor and industry attention around Kelun-Biotech’s ability to design and clinically advance ADCs. The company has also reported first-in-human data for SKB500, its B7-H3-directed ADC, and is progressing other conjugate programmes across solid tumors.
SKB565 broadens that franchise from target and payload optimization into integrated drug design. The programme may eventually provide evidence that the OptiDC platform can support more complex conjugates rather than only conventional toxin-carrying ADCs.
Commercially, however, SKB565 remains a long-duration option rather than a near-term revenue driver. Even a successful Phase 1 programme would need to be followed by indication selection, dose optimization, larger efficacy studies, manufacturing scale-up and regulatory submissions. Its immediate value is as a platform signal and a possible future licensing asset.
Kelun-Biotech reported 2025 revenue of approximately RMB2.06 billion and research and development expenditure of about RMB1.32 billion. The company remained loss-making, recording a loss attributable to shareholders of roughly RMB382 million, but its revenue base, commercial products and licensing relationships give it more development capacity than many early-stage ADC companies.
What does Kelun-Biotech’s recent share performance reveal about market expectations?
Available market data show that Kelun-Biotech shares closed at HK$514 on July 24, the final trading session before the SKB565 announcement. The stock had gained approximately 5.7% over the preceding five trading sessions and about 23% from its June 26 close, although it remained roughly 11.5% below its 52-week high of HK$581.
This suggests that investor sentiment was already constructive before the dual-payload ADC notice. Recent share-price momentum coincided with several broader developments, including late-stage sac-TMT data, progress across the clinical pipeline and the company’s July equity placing. The available evidence does not support attributing that performance specifically to SKB565.
The clinical trial announcement was released after the Hong Kong market had closed on July 27. An immediate market reaction therefore cannot be reliably assessed from the pre-announcement trading data.
For investors, the regulatory notice is best viewed as an incremental pipeline de-risking event. It removes the immediate regulatory barrier to beginning human testing but does not materially reduce biological, safety or efficacy risk. A more consequential revaluation would probably require evidence that the molecule has a workable therapeutic window and that both payloads contribute to clinically relevant activity.
Which SKB565 milestones will determine whether the platform promise survives clinical testing?
The first measurable milestone will be trial activation and enrolment of the initial dose-escalation patients. Kelun-Biotech will then need to demonstrate predictable pharmacokinetics, manageable early toxicity and sufficient exposure to support continued escalation.
The selection of a recommended Phase 2 dose will be another crucial point. Dual-payload ADCs may not follow the simple assumption that higher exposure produces better outcomes, particularly when one component stimulates immune activity. Dose optimization may require balancing tumor responses, toxicity and pharmacodynamic evidence from both payloads.
The eventual expansion cohorts should reveal which tumor types and biomarker-defined populations provide the clearest development path. A broad advanced-solid-tumor study can identify early signals, but commercial and regulatory progress will require Kelun-Biotech to narrow the programme to indications where target expression, biology and treatment need align.
Longer-term credibility will depend on durable responses, interpretable biomarker findings and evidence that the immunomodulatory payload adds value beyond the toxin. Manufacturing consistency and the ability to scale a technically complex conjugate will matter before any registrational programme can begin.
SKB565 has now crossed the boundary from a preclinical concept to a clinical-stage asset. The clinical trial notice validates Kelun-Biotech’s ability to advance the molecule through China’s IND review process, but the scientific proposition remains untested in patients. The decisive question is no longer whether a toxin and an immunomodulator can be attached to the same ADC. It is whether Kelun-Biotech can control both mechanisms well enough to produce a therapeutic window that justifies the added complexity.
